Jaclyn Frances Hechtman

List of Publications by Year
in descending order

86 papers	10,178 citations	101543 36 h-index	54911 84 g-index
87 all docs	87 docs citations	87 times ranked	16427 citing authors

#	Article	IF	Citations
1	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473
2	Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT). Journal of Molecular Diagnostics, 2015, 17, 251-264.	2.8	1,566
3	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell, 2018, 33, 125-136.e3.	16.8	589
4	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncology, 2019, 5, 471.	7.1	426
5	Genetic diversity of tumors with mismatch repair deficiency influences antiâ€“PD-1 immunotherapy response. Science, 2019, 364, 485-491.	12.6	395
6	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clinical Cancer Research, 2019, 25, 2116-2126.	7.0	390
7	NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Modern Pathology, 2020, 33, 38-46.	5.5	373
8	Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. American Journal of Surgical Pathology, 2017, 41, 1547-1551.	3.7	353
9	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discovery, 2018, 8, 49-58.	9.4	275
10	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 821-831.	10.7	243
11	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€“Anal Task Forces whitepaper. Nature Reviews Clinical Oncology, 2020, 17, 757-770.	27.6	218
12	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clinical Cancer Research, 2019, 25, 967-976.	7.0	164
13	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Modern Pathology, 2016, 29, 1433-1442.	5.5	144
14	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine, 2019, 25, 1422-1427.	30.7	144
15	A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. Clinical Cancer Research, 2016, 22, 2351-2358.	7.0	141
16	Detection ofNTRKFusions: Merits and Limitations of Current Diagnostic Platforms. Cancer Research, 2019, 79, 3163-3168.	0.9	138
17	EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discovery, 2019, 9, 199-209.	9.4	115
18	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. Cancer Research, 2019, 79, 1047-1053.	0.9	112

#	Article	IF	Citations
19	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clinical Cancer Research, 2020, 26, 1624-1632.	7.0	103
20	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. Journal of Molecular Diagnostics, 2017, 19, 244-254.	2.8	96
21	Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusionâ€“Positive Lung Cancer by Combining Selpercatinib with Crizotinib. Clinical Cancer Research, 2021, 27, 34-42.	7.0	87
22	HER2/neu Gene Amplification and Protein Overexpression in Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Histopathology, Diagnostic Testing, and Clinical Implications. Archives of Pathology and Laboratory Medicine, 2012, 136, 691-697.	2.5	82
23	Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphologyâ€“molecular associations: clinical and biological implications. Modern Pathology, 2017, 30, 599-609.	5.5	74
24	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 6160-6169.	7.0	73
25	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology, 2021, 74, 1429-1444.	7.3	73
26	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature Communications, 2021, 12, 3770.	12.8	68
27	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Research, 2017, 77, 6513-6523.	0.9	58
28	Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. Modern Pathology, 2020, 33, 871-879.	5.5	58
29	Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. Clinical Cancer Research, 2017, 23, 4753-4760.	7.0	56
30	MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nature Communications, 2017, 8, 14674.	12.8	53
31	Lineage Reversion Drives WNT Independence in Intestinal Cancer. Cancer Discovery, 2020, 10, 1590-1609.	9.4	52
32	Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). Modern Pathology, 2015, 28, 1123-1129.	5.5	51
33	Additional Primary Malignancies in Patients with Gastrointestinal Stromal Tumor (GIST): A Clinicopathologic Study of 260 Patients with Molecular Analysis and Review of the Literature. Annals of Surgical Oncology, 2015, 22, 2633-2639.	1.5	46
34	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Molecular Cancer Research, 2016, 14, 296-301.	3.4	46
35	Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. Journal of Clinical Investigation, 2018, 128, 3819-3825.	8.2	45
36	Clinical and genetic determinants of ovarian metastases from colorectal cancer. Cancer, 2017, 123, 1134-1143.	4.1	43

#	Article	IF	Citations
37	A Performance Comparison of Commonly Used Assays to Detect RET Fusions. Clinical Cancer Research, 2021, 27, 1316-1328.	7.0	39
38	Hepatocellular Carcinoma Arising in a Pigmented Telangiectatic Adenoma With Nuclear Î²-catenin and Glutamine Synthetase Positivity. American Journal of Surgical Pathology, 2011, 35, 927-932.	3.7	37
39	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. Cancer Discovery, 2021, 11, 126-141.	9.4	34
40	Germline SDHA mutations in children and adults with cancer. Journal of Physical Education and Sports Management, 2018, 4, a002584.	1.2	33
41	Carcinomas assemble a filamentous CXCL12â€“keratin-19 coating that suppresses T cellâ€“mediated immune attack. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	32
42	Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing. Genes Chromosomes and Cancer, 2015, 54, 177-184.	2.8	28
43	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. Modern Pathology, 2019, 32, 110-121.	5.5	28
44	V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer. Cancer Discovery, 2019, 9, 1182-1191.	9.4	27
45	Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma. Oncotarget, 2016, 7, 50875-50882.	1.8	26
46	Reliable Clinical MLH1 Promoter Hypermethylation Assessment Using a High-Throughput Genome-Wide Methylation Array Platform. Journal of Molecular Diagnostics, 2020, 22, 368-375.	2.8	25
47	Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. Molecular Cancer Research, 2017, 15, 708-713.	3.4	24
48	Carcinoma Ex Microcystic Adenoma of the Pancreas. American Journal of Surgical Pathology, 2012, 36, 305-310.	3.7	23
49	Characterization and Clinical Outcomes of DNA Mismatch Repairâ€“deficient Small Bowel Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1429-1437.	7.0	23
50	Promyelocytic leukemia zinc finger and histone H1.5 differentially stain low- and high-grade pulmonary neuroendocrine tumors: a pilot immunohistochemical study. Human Pathology, 2013, 44, 1400-1405.	2.0	21
51	FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. Clinical Colorectal Cancer, 2019, 18, e39-e52.	2.3	21
52	AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. Molecular Cancer Research, 2015, 13, 1003-1008.	3.4	20
53	Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. Annals of Surgical Oncology, 2018, 25, 2027-2033.	1.5	19
54	ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance. Human Pathology, 2016, 53, 97-104.	2.0	18

#	Article	IF	Citations
55	Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations. Familial Cancer, 2017, 16, 525-529.	1.9	18
56	Current Management of Appendiceal Neoplasms. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 118-132.	3.8	18
57	Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications. Human Pathology, 2017, 62, 74-82.	2.0	17
58	Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations. Familial Cancer, 2018, 17, 225-228.	1.9	17
59	Neurogenic Polyps of the Gastrointestinal Tract: A Clinicopathologic Review With Emphasis on Differential Diagnosis and Syndromic Associations. Archives of Pathology and Laboratory Medicine, 2015, 139, 133-139.	2.5	16
60	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. JAMA Network Open, 2021, 4, e2114753.	5.9	15
61	Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA. Human Pathology, 2019, 83, 1-6.	2.0	14
62	EBV-associated lymphoepithelioma-like carcinoma of the pancreas: Case report with targeted sequencing analysis. Pancreatology, 2015, 15, 302-304.	1.1	13
63	Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants. Human Pathology, 2020, 106, 45-53.	2.0	13
64	Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade. Modern Pathology, 2019, 32, 1551-1562.	5.5	12
65	EGFR Amplification in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2021, 113, 1561-1569.	6.3	12
66	Ischemic bowel due to embolization from an isolated mobile thrombus of the ascending aorta: a case report and review of the literature. Journal of Thrombosis and Thrombolysis, 2011, 32, 238-241.	2.1	10
67	Efficacy of Combined VEGFR1-3, PDGFÎ±/Î², and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 3811-3817.	7.0	10
68	Regorafenib in Combination with Firstâ€Line Chemotherapy for Metastatic Esophagogastric Cancer. Oncologist, 2020, 25, e68-e74.	3.7	10
69	Pan-Cancer Biomarkers: Changing the Landscape of Molecular Testing. Archives of Pathology and Laboratory Medicine, 2021, 145, 692-698.	2.5	10
70	Genomic stratification beyond Ras/Bâ€Raf in colorectal liver metastasis patients treated with hepatic arterial infusion. Cancer Medicine, 2019, 8, 6538-6548.	2.8	8
71	Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies. Familial Cancer, 2020, 20, 201-213.	1.9	8
72	Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways. Clinical Cancer Research, 2021, 27, 3491-3498.	7.0	8

#	Article	IF	Citations
73	Thymomas diagnosed during pregnancy: two cases in young women without paraneoplastic or autoimmune disease. Annals of Diagnostic Pathology, 2012, 16, 392-396.	1.3	7
74	Intraductal Polypoid Lipid-Rich Neuroendocrine Tumor of the Pancreas with Entrapped Ductules: Case Report and Review of the Literature. Endocrine Pathology, 2013, 24, 30-35.	9.0	5
75	Intramuscular corpora amylacea adjacent to ileal low-grade neuroendocrine tumours (typical) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf Pathology, 2013, 66, 569-572.	2.0	5
76	Multiple Endocrine Neoplasia Type 1 Associated With a New Mutation in the Menin Gene and a Midgut Neuroendocrine Tumor. Pancreas, 2014, 43, 145-146.	1.1	5
77	Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts. JCO Precision Oncology, 2022, 6, e2100242.	3.0	5
78	Anti-Glutamate Receptor 2 as a New Potential Diagnostic Probe for Prostatic Adenocarcinoma. Applied Immunohistochemistry and Molecular Morphology, 2012, 20, 344-349.	1.2	4
79	Mycobacterial pseudotumor of the plantar fascia: how common is it?. Clinical Imaging, 2013, 37, 802-805.	1.5	4
80	Subclinical focal cholangitis mimicking liver metastasis in asymptomatic patients with history of pancreatic ductal adenocarcinoma and biliary tree intervention. Cancer Imaging, 2017, 17, 21.	2.8	4
81	Corpora amylacea in gastrointestinal leiomyomas: a clinical, light microscopic, ultrastructural and immunohistochemical study with comparison to hyaline globules. Journal of Clinical Pathology, 2013, 66, 951-955.	2.0	3
82	The past, present, and future of HER2 (ERBB2) in cancer: Approaches to molecular testing and an evolving role in targeted therapy. Cancer Cytopathology, 2019, 127, 428-431.	2.4	1
83	Reply to Singh et al.. Modern Pathology, 2021, 34, 1033-1034.	5.5	1
84	Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer. JCO Precision Oncology, 2022, 6, e2100365.	3.0	1
85	Hepatic Mass in a 73-Year-Old Man. Gastroenterology, 2012, 142, 434-679.	1.3	0
86	Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies. Blood, 2017, 130, 794-794.	1.4	0